Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is sweeping the world since the end of 2019. The titer change of antibodies against SARS‐CoV‐2 needs to be further clarified, the clinical and preventive value of antibodies still needs to be further investigated. An enzyme‐linked immunosorbent assay (ELISA) was established by coating with SARS‐CoV‐2 recombinant spike protein and used to detect serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against SARS‐CoV‐2 in coronavirus disease 2019 patients to evaluate the pattern of changes of antibodies. The specificity of the ELISA for detection SARS‐CoV‐2 IgM and IgG were 96% (144/150) and 100% (150/150), respectively. The sensitivity of ELISA was 100% (150/150) for IgM, and 99.3% (149/150) for IgG. SARS‐CoV‐2‐SP‐IgM and SP‐IgG antibodies could be detected on Day 1 of hospitalization in 12.5% patients, and SP‐IgM began to decrease after reaching its peak at around 22–28 days, and become negative at Month 3 in 30% patients and negative at Month 7 in 79% of these patients after onset; IgG reached its peak around Day 22–28 and kept at a high level within the longest observation period for 4 months, it dropped very sharply at 7 months. The positive rates of SP‐IgM and SP‐IgG were higher than those of reverse transcription‐polymerase chain reaction on Day 7 and 4. The established indirect ELISA has good specificity and sensitivity. IgM and IgG against SARS‐CoV‐2 appeared almost simultaneously in the early stage, and the level of IgG antibodies could not maintain a high plateau in the observation period of 7 months. Our data will help develop the diagnosis and vaccine of SARS‐CoV‐2.
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by the SFTS virus (SFTSV), which has high mortality rates and poses a significant threat to public health. To identify potential therapeutic targets against SFTSV, we conduct genome-wide knockout screening, which identifies the previously known host factor CCR2, and reveals prolow-density lipoprotein receptor-related protein 1 (LRP1) as an entry factor for SFTSV. Knockdown or knockout of LRP1 significantly attenuate SFTSV infection in mouse embryonic fibroblasts (MEFs). Additionally, inhibition of LRP1 suppresses SFTSV pseudovirus infection in MEFs, suggesting its role in viral entry. The interaction between the SFTSV glycoprotein Gn and LRP1 via the CLI and CLII domains is revealed by co-IP and surface plasmon resonance (SPR). Moreover, LRP1 antagonists and neutralizing antibodies effectively attenuate SFTSV infection in MEFs. Administration of an LRP1-neutralizing antibody in a lethal male mouse model reduces the viral load, mitigates tissue damage, and improves survival. This study identifies LRP1 as a host entry receptor for SFTSV, providing a target for therapeutic strategy development.
While IgM and IgG response to SARS-CoV-2 has been extensively studied, relatively little is known about secretory IgA (sIgA) response in respiratory mucosa. Here we report IgA response to the SARS-CoV-2 in sputum, throat swabs, and serum with nucleocapsid protein (NP) enzyme-linked immunosorbent assays (ELISA) in a cohort of 28 COVID-19 patients and 55 vaccine recipients. The assays showed sIgA in respiratory mucosa could be detected on the first day after illness onset (AIO), and the median conversion time for sIgA in sputum, throat swabs, and serum was 3, 4, and 10 days, respectively. The positive rates of sIgA first week AIO were 100% (24/28) and 85.7% (24/28) in sputum and throat swabs, respectively, and were both 100% during the mid-onset (2–3 weeks AIO). During the recovery period, sIgA positive rates in sputum and throat swabs gradually decreased from 60.7% (17/28) and 57.1% (16/28) 1 month AIO and the sIgA antibodies were all undetectable 6 months AIO. However, serum IgA positive rate was still 100% at 4 months and 53.6% (15/28) at 6 months. Throat swabs obtained from volunteers who received inactivated SARS-CoV-2 vaccines by intramuscular delivery all showed negative results in IgA ELISA. These findings will likely improve our understanding of respiratory mucosal immunity of this emerging disease and help in containing the pandemic and developing vaccines.
Hepatocellular carcinoma (HCC) is a common malignant tumor with high extent of invasiveness. Its invasion process is closely related to complex tumor microenvironment and microvascular characteristics. Recently, immune combined targeted therapy has been applied to patients, combination therapy program with better effect needs to be explored. Atezolizumab combined Bevacizumab regimen in phase III clinical trial IMbrave150 was approved by U.S. Federal Drug Administration (FDA) for HCC treatment. This program is mostly used for liver malignant tumors have failed other treatments. Patients in terminal stage, overall curative has an unsatisfactory effect, survival time of patients is limited. Therefore, seeking best plan for combined treatment to improve patient's life quality and survival rate are still one of the most important clinical difficulties. This report describes a 37-year-old male who suffered from HCC repeatedly relapsed after hepatectomy. The patient received transcatheter arterial chemoembolization (TACE), microwave ablation (MWA), targeted therapy, and other combined treatments, all showed poor treatment effects. He received liver transplantation (LT) after receiving PD-1 blockade combined targeted therapy, eventually died due to severe immune rejection. It's first case of an allogeneic liver transplantation patient who received PD-1 blockade and Lenvaxen combined therapy. PD-1 blockade treatment and clinical observations of this case were summarized.
Spotted fever group Rickettsia (SFGR) poses a significant challenge in the field of tick-borne diseases, characterized by its obligate intracellular lifestyle and its ability to disrupt various host cellular pathways. A deeper understanding of Rickettsia ’s interactions with immune signaling is crucial for the development of novel therapeutic strategies. While previous research has shown that SFGR infection manipulates host cell death responses, the specific effects on receptor-interacting protein kinase 1 (RIPK1)-mediated multiple cell death pathways—collectively referred to as PANoptosis—remain poorly understood. In this study, we reveal that infection with Rickettsia heilongjiangensis suppresses RIPK1 kinase-dependent apoptosis and necroptosis in human microvascular endothelial cells (HMEC-1). However, mitochondria-dependent apoptosis during the late stages of infection is essential for bacterial replication. Interestingly, inhibition of caspase-8 does not sensitize Rickettsia -infected host cells to necroptosis. Transcriptomic analysis further reveals that Rickettsia infection upregulates the host tumor necrosis factor (TNF) and NF-κB signaling pathways, which subsequently suppress RIPK1 kinase activity and contribute to the inhibition of host cell death. These findings provide new insights into the molecular mechanisms by which Rickettsia evades host defenses.
BackgroundRickettsia felis causes febrile illness in humans. There is no information on the organism in Anhui Province of China.MethodsQuesting ticks were collected from Anhui Province of China and tick DNA was used as template for nested PCR (or real-time PCR) to amplify Rickettsia felis with 16S rRNA gene (rrs), 17kDa protein gene and orfB gene.ResultsPCR results indicated that 0.22% (2/907) ticks were positive to R. felis. Sequence analysis of the partial rrs and 17 kDa protein genes showed R. felis in ticks was highly homologous with R.felis URRWXCal2 with similarity of 98.91% and 99%, respectively.ConclusionsOur study demonstrated the first evidence of R. felis in H. longicornis ticks from Anhui Province of China, suggesting that a potential transmission of R. felis to humans through tick bite in China.